C07K 14/4748
Tumour specific antigens
Official title: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
C07K14/4748 (Tumour specific antigens) appears on 2,314 US grants and 4,215 published applications in this corpus.
Search patents in C07K- Granted patents
- 2,314
- Published applications
- 4,215
- Assignees
- 867
- Inventors
- 3,492
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 2 | 0 |
| 1980 | 3 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 16 | 0 |
| 1997 | 20 | 0 |
| 1998 | 33 | 0 |
| 1999 | 31 | 0 |
| 2000 | 35 | 0 |
| 2001 | 51 | 6 |
| 2002 | 36 | 105 |
| 2003 | 42 | 1235 |
| 2004 | 52 | 129 |
| 2005 | 35 | 123 |
| 2006 | 61 | 144 |
| 2007 | 185 | 95 |
| 2008 | 175 | 110 |
| 2009 | 81 | 96 |
| 2010 | 76 | 100 |
| 2011 | 80 | 103 |
| 2012 | 57 | 87 |
| 2013 | 63 | 59 |
| 2014 | 46 | 78 |
| 2015 | 46 | 52 |
| 2016 | 55 | 100 |
| 2017 | 40 | 99 |
| 2018 | 96 | 158 |
| 2019 | 133 | 178 |
| 2020 | 162 | 238 |
| 2021 | 153 | 199 |
| 2022 | 114 | 221 |
| 2023 | 91 | 189 |
| 2024 | 114 | 155 |
| 2025 | 81 | 100 |
| 2026 | 34 | 56 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Selection of cancer mutations for generation of a personalized cancer vaccine29 Sep 2026US 12,749,556 B2Nouscom AG
- Albumin-proaerolysin prodrugs28 Jul 2026US 12,691,158 B2The Johns Hopkins University
- Cell/gene therapies targeting MAGE-A4 peptide21 Jul 2026US 12,685,774 B2Innovative Cellular Therapeutics Holdings, Ltd.
- WT1 vaccine30 Jun 2026US 12,668,616 B2Inovio Pharmaceuticals, Inc.
- T-cell immunotherapy specific for WT-116 Jun 2026US 12,653,886 B2Fred Hutchinson Cancer Center
- Ligand discovery and gene delivery via retroviral surface display8 Oct 2026US 2026/0309700 A1Massachusetts Institute of Technology
- Immunotherapeutics based on magea1-derived epitopes1 Oct 2026US 2026/0297156 A1Max-DelbrüCk-Centrum FüR Molekulare Medizin In Der Helmholtz-Gemeinschaft
- Gm2 activator vectors and methods for use thereof1 Oct 2026US 2026/0297618 A1Gencorrex Therapies Inc.
- Novel tumor antigens for melanoma and uses thereof24 Sep 2026US 2026/0284166 A1Universite de Montreal
- Tumor-Specific Neoantigens and Methods of Using the Same24 Sep 2026US 2026/0285928 A1Geneos Therapeutics, Inc.
Most cited
By later US patents
- Anti-tumor antibody compositions and methods of use153US 6,824,780 B1Genentech, Inc. · 2004
- Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein139US 5,840,839 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 1998
- Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1138US 5,342,774 ALudwig Institute for Cancer Research · 1994
- Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules124US 7,833,970 B2Immatics Biotechnologies GmbH · 2010
- Monoclonal antibody to novel antigen associated with human tumors122US 5,171,665 AOncogen · 1992